秋水仙碱对冠脉PCI术后患者高敏c反应蛋白的影响
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v8i1.18656
Abstract
目的：本研究观察秋水仙碱联合标准治疗对冠脉PCI术后患者高敏c反应蛋白(hsCRP)的影响和临床疗效。方法：选择2023年6月-2024年6月在重庆市璧山区人民医院心血管内科内行冠脉PCI患者100例。随机分为对照组(50例)和秋水仙碱组(50例),对照组给予冠心病标准治疗,秋水仙碱组是在对照组基础上加用秋水仙碱。对比两组数据,观察PCI术后hsCRP浓度。结果：术后24小时：秋水仙碱组hsCRP变化率中位数(13.2%)仅为对照组(68.5%)的19.3%。术后1周：秋水仙碱组hsCRP变化率中位数(-3.5%)呈负向(接近基线),而对照组仍为正向升高(45.3%)。
Keywords
秋水仙碱；冠状动脉粥样硬化性心脏病；冠状动脉pci；高敏c反应蛋白
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 中华医学会心血管病学分会。经皮冠状动脉介入治疗术后管理中国专家共识(2023版)[J].中华心血管病杂志,2023,51
[2] Jernberg T,Hasvold P,Henriksson M,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term persp
[3] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med 1999;340:115-26.
[4] 李为民,韩雅玲.老年冠心病患者经皮冠状动脉介入治疗中国专家共识(2022)[J].中华老年心脑血管病杂志,2022,24(8):801
[5] deWinterRJ, Heyde GS, Koch KT, et al. The prognostic value of preprocedural plasma C-reactive protein in patients undergoing elective coronary angioplasty[J].Eur Heart J 2002;
[6] Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease[J]. Eur Heart J 2004;25:401-8.
[7] Habib M,Salama I,Agha HA, et al. Colchicine treatment for prevention of in stent restenosis (CISR trial)[J]. American J Emerg Crit Care Med 2019;2:001-5.
[8] Ren F, Mu N,Zhang X,Tan J,Li L,Zhang C,Dong M. Increased platelet-leukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction
[9] Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase
[2] Jernberg T,Hasvold P,Henriksson M,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term persp
[3] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med 1999;340:115-26.
[4] 李为民,韩雅玲.老年冠心病患者经皮冠状动脉介入治疗中国专家共识(2022)[J].中华老年心脑血管病杂志,2022,24(8):801
[5] deWinterRJ, Heyde GS, Koch KT, et al. The prognostic value of preprocedural plasma C-reactive protein in patients undergoing elective coronary angioplasty[J].Eur Heart J 2002;
[6] Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease[J]. Eur Heart J 2004;25:401-8.
[7] Habib M,Salama I,Agha HA, et al. Colchicine treatment for prevention of in stent restenosis (CISR trial)[J]. American J Emerg Crit Care Med 2019;2:001-5.
[8] Ren F, Mu N,Zhang X,Tan J,Li L,Zhang C,Dong M. Increased platelet-leukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction
[9] Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase
Copyright © 2026 涂植涛, 郭婷
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License